MX2021006542A - Inhibidores de la usp19 para usarse en terapia. - Google Patents
Inhibidores de la usp19 para usarse en terapia.Info
- Publication number
- MX2021006542A MX2021006542A MX2021006542A MX2021006542A MX2021006542A MX 2021006542 A MX2021006542 A MX 2021006542A MX 2021006542 A MX2021006542 A MX 2021006542A MX 2021006542 A MX2021006542 A MX 2021006542A MX 2021006542 A MX2021006542 A MX 2021006542A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- usp19
- therapy
- inhibitors
- treating
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 101150006083 USP19 gene Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 101000644843 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 19 Proteins 0.000 abstract 3
- 102100020728 Ubiquitin carboxyl-terminal hydrolase 19 Human genes 0.000 abstract 3
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 201000000585 muscular atrophy Diseases 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 208000001076 sarcopenia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1819936.4A GB201819936D0 (en) | 2018-12-06 | 2018-12-06 | Therapeutic methods |
| GBGB1904341.3A GB201904341D0 (en) | 2019-03-28 | 2019-03-28 | Therapeutic methods |
| PCT/GB2019/053456 WO2020115500A1 (en) | 2018-12-06 | 2019-12-06 | Usp19 inhibitors for use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021006542A true MX2021006542A (es) | 2021-07-07 |
Family
ID=68887434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006542A MX2021006542A (es) | 2018-12-06 | 2019-12-06 | Inhibidores de la usp19 para usarse en terapia. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220016115A1 (https=) |
| EP (1) | EP3890737B1 (https=) |
| JP (1) | JP2022510700A (https=) |
| KR (1) | KR20210100127A (https=) |
| CN (1) | CN113395965A (https=) |
| AU (1) | AU2019393161A1 (https=) |
| BR (1) | BR112021010645A2 (https=) |
| CA (1) | CA3121422A1 (https=) |
| IL (1) | IL283687A (https=) |
| MX (1) | MX2021006542A (https=) |
| SG (1) | SG11202105911PA (https=) |
| WO (1) | WO2020115500A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3965749A4 (en) * | 2019-05-06 | 2023-06-21 | Valo Health, Inc. | ESCAPEMENT OF USP19 |
| GB202104097D0 (en) | 2021-03-24 | 2021-05-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB202311227D0 (en) | 2023-07-21 | 2023-09-06 | Almac Discovery Ltd | Pharmaceutical compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO111096A0 (en) * | 1996-07-18 | 1996-08-08 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| TW200930713A (en) | 2007-12-03 | 2009-07-16 | Takeda Pharmaceutical | Nitrogen-containing heterocyclic compound and use thereof |
| CN104174021A (zh) * | 2013-05-22 | 2014-12-03 | 复旦大学附属华山医院 | 蛋白酶体抑制剂在制备治疗慢性低度炎症性疾病药物中的用途 |
| AR103297A1 (es) * | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
| GB201612938D0 (en) * | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
| CA3072353A1 (en) * | 2017-09-26 | 2019-04-04 | Dana-Farber Cancer Institute, Inc. | Usp7 inhibitors for treating multiple myeloma |
| GB201801562D0 (en) * | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
-
2019
- 2019-12-06 MX MX2021006542A patent/MX2021006542A/es unknown
- 2019-12-06 US US17/299,971 patent/US20220016115A1/en not_active Abandoned
- 2019-12-06 SG SG11202105911PA patent/SG11202105911PA/en unknown
- 2019-12-06 EP EP19821175.7A patent/EP3890737B1/en active Active
- 2019-12-06 CA CA3121422A patent/CA3121422A1/en active Pending
- 2019-12-06 BR BR112021010645-6A patent/BR112021010645A2/pt not_active IP Right Cessation
- 2019-12-06 WO PCT/GB2019/053456 patent/WO2020115500A1/en not_active Ceased
- 2019-12-06 KR KR1020217019978A patent/KR20210100127A/ko not_active Withdrawn
- 2019-12-06 AU AU2019393161A patent/AU2019393161A1/en not_active Abandoned
- 2019-12-06 CN CN201980091404.7A patent/CN113395965A/zh active Pending
- 2019-12-06 JP JP2021532119A patent/JP2022510700A/ja active Pending
-
2021
- 2021-06-03 IL IL283687A patent/IL283687A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022510700A (ja) | 2022-01-27 |
| WO2020115500A1 (en) | 2020-06-11 |
| EP3890737A1 (en) | 2021-10-13 |
| IL283687A (en) | 2021-07-29 |
| CN113395965A (zh) | 2021-09-14 |
| BR112021010645A2 (pt) | 2021-08-17 |
| CA3121422A1 (en) | 2020-06-11 |
| US20220016115A1 (en) | 2022-01-20 |
| EP3890737B1 (en) | 2024-06-05 |
| SG11202105911PA (en) | 2021-07-29 |
| KR20210100127A (ko) | 2021-08-13 |
| AU2019393161A1 (en) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017382297A8 (en) | Phosphodiesterase inhibitors and methods of microbial treatment | |
| PH12020550936A1 (en) | Combination drug including tlr7 agonist | |
| EP4253412A3 (en) | Inhibition of cytokine-induced sh2 protein in nk cells | |
| GEAP202215479A (en) | Magl inhibitors | |
| MY191321A (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| WO2016077632A3 (en) | Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications | |
| DK3890740T3 (da) | CD70 og venetoclax, en BCL-2 inhibitor, kombinationsterapi til behandling af akut myeloid leukæmi | |
| MX2017000307A (es) | Tratamiento de leucemia con inhibidores de histona deacetilasa. | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| AU2018347307A1 (en) | Heterocyclic compounds and uses thereof | |
| EP4691567A3 (en) | Jak1 pathway inhibitor for use in the treatment of chronic lung allograft dysfunction | |
| EP4585273A3 (en) | Mechanism of resistance to bet bromodomain inhibitors | |
| EA201890728A2 (ru) | Лечение ингибиторами ntcp атеросклероза, первичного билиарного цирроза и заболевания, связанного с nrlp3-инфламмасомами | |
| MX2021006542A (es) | Inhibidores de la usp19 para usarse en terapia. | |
| PH12022550118A1 (en) | Enzyme inhibitors | |
| MX2022007285A (es) | Compuestos, polimeros, dispositivos y usos de los mismos. | |
| MX2021012418A (es) | Compuestos heterociclicos y sus usos. | |
| JOP20220007A1 (ar) | طرق للعلاج أو الوقاية من ضمور العضلات النخاعي | |
| MX2020008091A (es) | Derivados de 4-hidroxipiperidina y su uso como inhibidores de proteasa especifica de ubiquitina 19 (usp19). | |
| MX2021006540A (es) | Compuestos farmaceuticos y su uso como inhibidores de proteasa 19 especifica de ubiquitina (usp19). | |
| NZ733451A (en) | Combination therapy for pulmonary hypertension | |
| EP3952871A4 (en) | AKT DEGRADATION BY CONJUGATION OF ATP COMPETITIVE AKT INHIBITOR GDC-0068 WITH E3 LIGASE LIGANDS AND METHODS OF USE | |
| MX2020001546A (es) | Uso de inhibidores de braf para tratar reacciones cutaneas causadas por el tratamiento con un inhibidor de mek. | |
| EP4234022A3 (en) | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | |
| MX2020011912A (es) | Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc). |